Behçet’s disease: ulcers, eye risks and vascular treatment

Behçet’s disease, also called Behçet’s syndrome, is a relapsing inflammatory disorder that can involve arteries, veins and several organs. Vasculitis Foundation definition. Recurrent mouth or genital ulcers are common clues, but ulcers alone do not establish the diagnosis. Confidence is high that new eye, neurological or vascular symptoms need timely assessment; comparative treatment certainty is lower and depends on the affected organ.

Table of contents

• Evidence summary
• What Behçet’s disease is: ulcers, eyes and variable-vessel disease
• Mechanisms and diagnosis: HLA-B51, pathergy and clinical assessment
• Treatment: mucocutaneous symptoms versus organ-threatening disease
• Supplement and lifestyle evidence
• What works and what remains uncertain: the anticoagulation disagreement
• Risks and urgent warning signs
• Interactions: colchicine, immune medicines and pregnancy
• Who needs assessment: recurrent ulcers, children and changing symptoms
• Clinician-led care and follow-up
• Animal and in vitro evidence
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

The central question is which tissue is affected and whether function is threatened. NHLBI treatment context. A plan for painful ulcers cannot be assumed to protect vision or treat an inflamed artery.

The original 2025 UK living guideline and EULAR update published March 2026 are attributed clinical frameworks with disclosed company relationships. This guide does not convert their recommendations into an industry-free ranking or a promised individual response.

What Behçet’s disease is: ulcers, eyes and variable-vessel disease

The name is often written without accents as Behcet disease. “Disease” and “syndrome” refer to the same clinical family. The Foundation guide describes variable-size vessel involvement, with possible skin, joint, eye, bowel, brain or spinal-cord manifestations. People can have different combinations over time.

The NHS overview describes periods of symptoms and periods of relative improvement. The condition is chronic; current care aims to control manifestations and complications rather than offer a guaranteed cure. A symptom that appears later deserves assessment even after a long stable interval.

A genital ulcer caused by Behçet’s is not a sexually transmitted infection. Pediatric Foundation explanation. That does not identify the cause of every genital sore: an undiagnosed lesion may require infection or sexual-health assessment. Record symptoms without assuming either infection or Behçet’s.

This is distinct from an ordinary recurring canker sore and from atherosclerosis. The practical distinction is the wider pattern of inflammatory findings and organ risks, not simply how painful one mouth lesion feels. A prior diagnostic label should explain the current findings, not prevent consideration of another cause.

Mechanisms and diagnosis: HLA-B51, pathergy and clinical assessment

The cause remains incompletely understood; immune, genetic and environmental factors may contribute. NHLBI cause context. A suspected trigger in one person is not proof that a food, infection or supplement explains all disease.

HLA-B51 is associated with Behçet’s, but it also occurs in people without the disease. Foundation diagnostic explanation. Its presence does not confirm the diagnosis, and a result must be interpreted with the clinical pattern. A consumer genetic report cannot replace organ assessment.

The pediatric guide describes pathergy: an exaggerated skin reaction after a medically performed needle test. Positive and negative results can both occur outside the expected pattern, so this is supportive rather than decisive. Do not attempt a home needle-prick test.

History, examination and targeted testing help assess affected organs and exclude alternatives. NHLBI assessment context. Keep a dated account of lesions, eye symptoms, joint swelling and other changes; a photograph may help document an episode but cannot determine the whole diagnosis.

The UK original discusses clinical criteria and evolving/incomplete presentations. Classification systems support structured assessment; a self-calculated score is not a diagnosis. An unusual course should prompt review of mimics rather than escalating immune treatment solely to fit a checklist.

Treatment: mucocutaneous symptoms versus organ-threatening disease

The NHS treatment guide describes topical treatment for ulcers and systemic anti-inflammatory or immune medicines for selected disease. Care may involve rheumatology, dermatology, oral medicine and organ specialists. Its dated medicine sequence is not a substitute for the newer guidance.

Current EULAR guidance separates mucocutaneous, joint, ocular, vascular, bowel and neurological care. Colchicine and selected immune therapies have different clinical roles. Treatment choice should specify the target manifestation, previous response and safety constraints; this article does not supply a universal drug ladder.

The UK guideline distinguishes local eye treatment from systemic care for more serious ocular disease. A cream, mouth rinse or steroid eye drop is not automatically an adequate plan for posterior eye involvement. Ophthalmology findings determine the concern.

The September 2026 US Amgen label gives apremilast an adult Behçet’s oral-ulcer indication. That regulatory scope does not establish treatment of aneurysms, neurological disease or every Behçet’s manifestation. Manufacturer-issued efficacy is excluded from this article’s independent verdict.

Vascular or bowel procedures may address a complication while immune care addresses inflammation. NHLBI general treatment explanation. Ask what each intervention is intended to accomplish and what remains to monitor. Neither an intervention nor a prescription removes the need to assess new symptoms.

Supplement and lifestyle evidence

No conflict-cleared human evidence inspected here establishes a supplement as treatment for Behçet’s or prevention of organ damage. NCCIH supplement safety. “Anti-inflammatory” or “immune-balancing” marketing does not show preserved vision, fewer vascular complications or a useful clinical response.

The NHS mouth-ulcer guide suggests a soft toothbrush and avoiding irritating foods or drinks for comfort. These measures can make eating and oral care easier. They do not demonstrate control of systemic inflammation or make urgent eye symptoms safe to observe at home.

A nutritional deficiency may need its own investigation and treatment. That is a separate indication from disease modification. Record the actual product, ingredients and intended purpose so the pharmacist can review it alongside prescription medicines.

Rest, activity adapted to symptoms and support at school/work can be discussed with the team. Pain, sleep and emotional burden deserve attention alongside organ surveillance. A practical adjustment should have a clear goal such as eating comfortably or maintaining daily function, rather than a claim that lifestyle measures cure the disease.

What works and what remains uncertain: the anticoagulation disagreement

The 2025 BAD/BSR guideline advises against adding anticoagulation to immune treatment for Behçet’s deep-vein thrombosis. The EULAR update published in March 2026 permits adding it when bleeding risk is low and pulmonary artery aneurysms have been excluded. These are different current recommendations, with limited evidence.

A specialist must assess the clot, inflammatory activity, aneurysm/bleeding risk and other reasons for anticoagulation. This article cannot resolve that disagreement for an individual. Do not start or stop an anticoagulant based on the general rule used for a different type of thrombosis.

The NHS symptoms page describes neurological disease and thrombosis in brain veins as different possible complications. “Neuro-Behçet’s” is not a single symptom or treatment decision. The location and mechanism matter; a new neurological symptom cannot be interpreted from mouth-ulcer activity.

Assessing improvement should include the target organ, symptoms, function and treatment harms. NHLBI organ context. An ulcer count may be relevant to oral disease, while vision and vessel findings require different measures. A response in one domain is not proof of improvement in another.

Evidence limitations are especially important when a recommendation relies on expert judgment or a small selected study. No inspected, conflict-cleared comparison establishes one medicine as best for every manifestation. Guidance and uncertainty can coexist without abandoning appropriate medical care.

Risks and urgent warning signs

New eye pain, redness, light sensitivity or blurred vision needs urgent eye assessment. Sudden loss of sight is an emergency. NHS uveitis advice. Do not wait for an ulcer flare or try leftover drops before seeking care.

Sudden weakness, speech difficulty, confusion, collapse or a severe new headache with neurological changes needs emergency assessment. Coughing blood or severe chest pain/breathlessness can also signal serious vascular or lung disease. NHS organ-complication context. State the Behçet’s diagnosis and medication list to the emergency team.

Persistent severe abdominal pain or bowel bleeding needs prompt medical review. NHS bowel-symptom context. A new symptom can have causes other than Behçet’s, including infection or a treatment complication. The diagnosis should not become a reason to delay investigation.

Immune medicines can increase infection risk and may require blood monitoring. NHS treatment safety. Fever or deterioration during treatment requires advice; relapse, infection and drug toxicity can need different management. Do not automatically treat every fever with an extra steroid dose.

The maker label warns about severe gastrointestinal effects, weight loss and mood/depression changes with apremilast. Discuss concerning effects promptly; suicidal thoughts need immediate help. These are attributed safety warnings, not incidence estimates or an independent efficacy endorsement.

Interactions: colchicine, immune medicines and pregnancy

Colchicine can become toxic with certain antibiotics, heart medicines, antivirals and other drugs; grapefruit juice can raise exposure. NHS colchicine guidance. Kidney/liver disease also changes suitability. Have a pharmacist review the actual list rather than applying a gout regimen to Behçet’s.

Taking more colchicine than prescribed needs urgent advice. Gastrointestinal illness, weakness or other serious symptoms during treatment may represent toxicity. Current safety advice. Do not assume diarrhoea is harmless because it is mentioned in a patient leaflet.

The Amgen label identifies strong enzyme-inducing medicines as an apremilast interaction and requires attention to renal impairment and pregnancy. The exact formulation and local label matter. No dose conversion or personal adjustment is supplied here.

Prednisolone needs review of other medicines, supplements and infection risk. NHS interaction context. Pregnancy planning should address both disease and the actual regimen, not a blanket rule that all immune medicines are unsafe. NHLBI pregnancy planning. Ask before changing a needed treatment.

Who needs assessment: recurrent ulcers, children and changing symptoms

Persistent, atypical or worsening mouth ulcers deserve dental or medical assessment. NHS ulcer advice. Alternatives include local injury, infection, deficiency and other inflammatory disease. Having mouth ulcers does not establish Behçet’s, and a persistent lesion should not be dismissed as another routine flare.

Recurrent mouth/genital lesions with eye, skin or joint problems warrant a fuller history. NHS overview. Explain the sequence and recurrence rather than bringing only the latest photograph. Different manifestations may not occur on the same day.

The pediatric guide notes that people from any ethnic background can be affected. A child’s assessment also needs attention to growth, development and the burden of treatment. Ethnicity, age or an absent family history should not substitute for a clinician’s assessment of the findings.

Known disease needs reassessment when symptoms change, treatment is poorly tolerated or function declines. Distinguish a routine review from a new urgent concern. An existing appointment weeks away is not the appropriate response to sudden vision loss or neurological symptoms.

Clinician-led care and follow-up

Agree on which clinician coordinates the plan and how eye, vascular, neurological or bowel concerns are referred. The NHS guide describes individualized care after diagnosis. Carry a concise record across services, including past organ involvement and any aneurysm history.

Document why each medicine is prescribed, how benefit is assessed and what tests are needed. If advice differs between specialists, ask them to reconcile the target manifestation and safety issue. A written anticoagulation decision is particularly useful when more than one service is involved.

Longer steroid treatment should not be abruptly stopped. NHS stopping guidance. Clarify tapering and illness instructions with the prescriber. These are safety decisions distinct from choosing which treatment to start.

A follow-up visit should leave space for eating, sexual health, fatigue, mood, work and family concerns. NHLBI daily-care context. Practical support can matter even when a scan or laboratory result is stable. Report both new symptoms and limitations that prevent ordinary activities.

For a young person moving to adult services, ensure the new team receives the actual diagnostic history, organ findings and medication rationale. A symptom diary can assist communication, but should not become a self-directed immune-treatment or anticoagulation schedule.

Animal and in vitro evidence

Cell and animal studies can explore immune signaling and vessel injury. A change in an inflammatory pathway does not establish that a supplement controls recurrent ulcers or prevents a human aneurysm.

Useful human outcomes include symptoms, daily function, sight, organ injury and treatment harms. Laboratory biomarkers cannot replace these outcomes. This guide excludes laboratory-to-human efficacy extrapolation and sponsor-funded benefit claims from the independent verdict.

Funding and source roles

BAD funds the UK guideline but offers commercial institutional partnerships, and printed author declarations include company relationships. EULAR funds its update and lists company ties among authors; society dues and corporate membership are separately documented. These clinical frameworks are attributed, with underlying trials not cleared. Amgen’s label is Tier 4/D for manufacturer self-interest and used only for its stated regulatory indication and warnings.

Tier describes financial proximity; A–D describes credibility for the stated source role. Neither is a clinical certainty grade. Unknown finances remain unknown. Manufacturer- and sponsor-funded efficacy is excluded from the independent verdict; attributed clinical guidance is identified as guidance.

Frequently asked questions

Are Behçet’s disease and Behcet syndrome different?
They are names for the same clinical family. The spelling often omits accents.

Does HLA-B51 confirm the diagnosis?
No. It is a risk association and cannot replace the clinical pattern and assessment of alternatives.

Are Behçet’s genital ulcers contagious?
The disease itself is not sexually transmitted. An undiagnosed genital lesion still needs assessment for other possible causes.

Should every Behçet’s clot receive anticoagulation?
No universal answer is supplied. Current guidelines differ, and the specialist must assess inflammation, bleeding/aneurysm risk and any other indication.

Does apremilast treat all organ involvement?
Its inspected US label specifies adult oral ulcers associated with Behçet’s. That does not establish a treatment for every organ manifestation.

When are eye symptoms urgent?
New painful/red eyes or visual changes need urgent assessment; sudden loss of sight is an emergency.

Sources and funding notes

The full 2025 BAD/BSR publisher HTML was opened with relevant clinical sections and printed funding/COI. EULAR’s primary journal-indexed 2025 update (published March 2026) provided clinical, methods and financial text; direct full article/PDF and separate detailed forms were unavailable. That access limit is retained. The NHS Behçet’s pages were last reviewed April 2023 and their scheduled review has passed; current guidance is distinguished from older summaries. The current Amgen label is manufacturer-authored despite NLM hosting. No personal dose, treatment-effect percentage or all-organ drug ranking is supplied.

• BAD/BSR: original 2025 living Behçet’s guideline — Current UK diagnostic/organ-care framework and attributed anticoagulation position.
• EULAR: original 2025 Behçet’s update, published March 2026 — Current European organ framework; anticoagulation advice differs from UK guideline. No independent drug ranking.
• NHS: Behçet’s overview (April 2023) — Definition and evolving clinical assessment; older mandatory-ulcer shorthand not adopted.
• NHS: Behçet’s symptoms (April 2023) — Oral/genital, skin, eye, vascular and neurological manifestations.
• NHS: Behçet’s treatment (April 2023) — General care coordination, immune-treatment monitoring and pregnancy context; older access/sequence claims not adopted.
• Vasculitis Foundation: Behçet’s syndrome (February 2024) — Variable-vessel definition, HLA-B51 limits and relapse context; no numerical outcomes adopted.
• Vasculitis Foundation: pediatric Behçet’s guide — Child-specific assessment, pathergy limits and transition/organ context; not adult trial efficacy.
• NHS: mouth ulcers (March 2024) — Comfort measures, alternative causes and assessment of persistent/atypical ulcers; not a Behçet’s diagnosis.
• NHS: uveitis (March 2024) — Urgent eye symptoms and vision-loss emergency; ophthalmology assessment rather than self-treatment.
• NHS: colchicine safety (August 2026) — Toxicity, overdose, kidney/liver and interaction cautions; gout doses are not a Behçet’s regimen.
• Amgen: Otezla/Otezla XR original US label (September 2026) — Adult Behçet’s oral-ulcer indication and attributed warnings only; sponsor efficacy excluded.
• BAD: original sponsorship and advertising opportunities — Own BAD financial routes; not proof a particular company funded the guideline.
• BSR: original sponsorship and partnership offers — Society income routes and headquarters; no proof of a named company funding the 2025 project.
• EULAR: membership/dues — Financial context only.
• EULAR: corporate membership list — Named institutional commercial ties only.
• Vasculitis Foundation: audited FY 2024–25 accounts — Institutional funding model only.
• Vasculitis Foundation: awareness fundraising sponsors — Named commercial relationship only.
• NHLBI: vasculitis overview (May 2023) — Disease-family definition and vessel-size context; not cleared treatment trials.
• NHLBI: causes (May 2023) — Possible triggers and secondary causes; not an individual causal diagnosis.
• NHLBI: symptoms (May 2023) — Organ-specific manifestations and complications.
• NHLBI: diagnosis (May 2023) — Clinical, blood, urine, biopsy and imaging assessment; subtype-specific accuracy not assumed.
• NHLBI: treatment (May 2023) — Attributed general treatment context, not a comparative efficacy verdict.
• NHLBI: living with vasculitis (May 2023) — Follow-up, pregnancy planning and emergency complications; individual risks differ.
• NHLBI: budget and gift authority — Funding trace, not outcome evidence.
• NHS: prednisolone side effects — Infection, bone, metabolic and mood risks; medicine safety, not disease-specific efficacy.
• NHS: prednisolone use and stopping (February 2022) — Clinician-directed tapering and adrenal safety; stated review date has passed.
• NHS: prednisolone interactions (February 2022) — NSAID/aspirin and supplement cautions; dated general medicine context.
• NHS website: content and funding policy — Website funding and editorial safeguards only.
• NCCIH: using dietary supplements wisely — Safety and interaction limits, not proof of vasculitis efficacy.

Last reviewed: October 4, 2026. Educational information; no personal diagnosis, medication dose or supplement regimen is supplied. Local approval, product labels and clinical circumstances may differ.